| Accession |
PRJCA013767 |
| Title |
A phase III clinical trial of PD-1 antibody SHR-1210 combined with apatinib mesylate versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HCC) |
| Relevance |
Medical |
| Data types |
clinical,image,Metabolic,Biomarker,Genetic data
|
| Organisms |
Homo sapiens
|
| Description |
Overall survival (OS) and progression-free survival (PFS) were evaluated to evaluate the efficacy of SHR-1210 combined with apatinib mesylate (trial group) versus sorafenib (control group) as first-line treatment for patients with advanced HCC |
| Sample scope |
Multiisolate |
| Release date |
2022-12-09 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| NA
|
|
NA
|
|
|
|
| Submitter |
wanqiu
liang (wanqiu.liang@hengrui.com)
|
| Organization |
Jiangsu Hengrui Pharmaceutical Co. LTD |
| Submission date |
2022-12-09 |
